Navigation Links
MAP Pharmaceuticals Acquires Proprietary Drug Particle Formulation Technology From Eiffel/Telesso Technologies Limited
Date:6/24/2008

MOUNTAIN VIEW, Calif., June 24 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that Telesso Technologies Limited, formerly Eiffel Technologies Limited ("Eiffel"), has agreed to transfer and assign to MAP Pharmaceuticals previously licensed intellectual property and know-how, as well as capital equipment, owned by Eiffel related to its supercritical fluid technology ("SCF").

MAP Pharmaceuticals will make payments to Eiffel upon the successful transfer of the intellectual property and related capital equipment. Eiffel will receive milestone payments upon achievement of certain late stage clinical and regulatory milestones for the first product developed by MAP Pharmaceuticals using the Eiffel technology. The new agreement supersedes the research and development agreement entered into by the companies in 2005 and eliminates all royalty and milestone commitments under the previous agreement.

Since 2005, MAP Pharmaceuticals and Eiffel have collaborated on the development of methods for manufacturing drug particles either alone, or as a combination of two drugs in a single particle, using Eiffel's SCF technology. The technology has been shown in clinical studies to be applicable to inhaled formulations of biologics and combination drug products. MAP Pharmaceuticals believes the technology may also apply to the combination of three different drugs into a single particle for inhalation or for use in other dosage forms.

"This acquisition allows MAP Pharmaceuticals to assume direct control of processing and manufacturing of drug formulations relating to the SCF technology, while also allowing full control of intellectual property," said Timothy S. Nelson, President and Chief Executive Officer
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...ment. What do you remember about your breakfast th... smell of coffee brewing, while another will remem...r. How does the brain weave together these fragmen...ife? , Researchers led by Prof. Itzhak Fried, a ...lty of Medicine, are proving scientifically what s...
(Date:12/4/2008)...ird of Americans with diabetes do not know that th...ditions are unaware that they are at risk. A Univ...al tool to identify those at highest risk for havi...ose (IFG) and undiagnosed diabetes. If these condi...rom preventative strategies that can minimize prog...
(Date:12/4/2008)...c. 4 Triple-S,Managemen...it has signed a non-,binding letter of intent to ...zul de Puerto Rico, Inc. In addition, the Company...transfer the licensing rights to the Blue Cross br...ield brands in the US Virgin Islands,to the Compa...
(Date:12/4/2008)...work(TM) to Administer Program , , BUFFALO,...inder(TM) Network has been selected by The Washing...r a Medication Therapy Management (MTM) program fo...UMP) and the Aetna Public Employees Plan of Washin...mmunity pharmacists to review prescriptions with p...
Breaking Medicine News(10 mins):Health News:Unlocking the mysteries of memory 2Health News:Researcher develops screening tool to identify patients with prediabetes 2Health News:Triple-S Management Corporation Signs Letter of Intent to Acquire Managed Care Portfolio of La Cruz Azul de Puerto Rico, Inc. 2Health News:Washington State Health Care Authority to Launch Medication Therapy Management Initiative 2
...esearchers at Seattle Childrens Hospital Research ...er will help surgeons see where a tumor begins an...s cells. The paint is a scorpion-derived peptide...he molecular beacon Cy5.5.Until now there has been...
...y of California, San Diego (UCSD) School of Medici...ave discovered that, 30 years ago, a virus infecte... flesh-eating bacteria that has evolved to produce...he incidence of serious strep infections has risen...
...er Institute for Learning and Memory have uncovere... of fears stemming from traumatic events . The wo...ons of adults who suffer each year from persistent...ng hundreds of soldiers returning from conflict in...
...rt and gum diseases at bay, but a new study has fo...eases the risk of breast cancer by almost a third ...ting the fruit can give the levels of oestrogen t...ith the risk of breast cancer a boost. The findi...
Other Medicine News:Health News:Tumor Painting to Fight Against Cancer 2Health News:Tumor Painting to Fight Against Cancer 3Health News:Key Mechanism to Emergence of Strep Bacteria 2Health News:Key Mechanism to Emergence of Strep Bacteria 3Health News:First Drug for Post-traumatic Stress Disorder 2
(Date:12/3/2008)... treatment alleviates long-term anemia and organ d...ions , , MEMPHIS, Tenn., Dec. 3 /PRNewswir...a corrective gene into mouse blood cells, scientis...lleviated sickle cell disease pathology. In their ...ce showed essentially no difference from normal mi...
(Date:12/3/2008)..., Pa., Dec. 3 Wyeth Phar...announced today that it has submitted a,marketing...edicines Agency,(EMEA) for approval to market its... vaccine (PCV13) for infants and young children. ... of pneumococcal disease (PD) caused by the 13,se...
(Date:12/3/2008)...lif., Dec. 3 Isis Pharma... that OncoGenex Pharmaceuticals, Inc.,provided po...clinical trial of,OGX-011 in combination with doc...d to docetaxel and prednisone alone ("the control ...rate resistant prostate cancer. The current 10.6,...
(Date:12/3/2008)...ec. 3 Vical Incorporated...binding letter of intent with EIP,Eczacibasi Ilac...he company,s,Allovectin-7(R) immunotherapeutic pr...c of Northern Cyprus. EIP has agreed to obtain the... and to pay Vical upfront and milestone payments,...
Breaking Medicine Technology:Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 2Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 3Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5MINRAD International Inc Announces 2007 Financial Results 15574 1MINRAD International Inc Announces 2007 Financial Results 15574 2MINRAD International Inc Announces 2007 Financial Results 15574 3MINRAD International Inc Announces 2007 Financial Results 15574 4MINRAD International Inc Announces 2007 Financial Results 15574 5MINRAD International Inc Announces 2007 Financial Results 15574 6MINRAD International Inc Announces 2007 Financial Results 15574 7MINRAD International Inc Announces 2007 Financial Results 15574 8MINRAD International Inc Announces 2007 Financial Results 15574 9MINRAD International Inc Announces 2007 Financial Results 15574 10MINRAD International Inc Announces 2007 Financial Results 15574 11MINRAD International Inc Announces 2007 Financial Results 15574 12Transgenomic Opens Pharmacogenomics Laboratory in China 4293 1Transgenomic Opens Pharmacogenomics Laboratory in China 4293 2Transgenomic Opens Pharmacogenomics Laboratory in China 4293 3Gen Probe Begins U S Clinical Study of Molecular Test for Human Papillomavirus Which Causes Cervical Cancer 1645 1Gen Probe Begins U S Clinical Study of Molecular Test for Human Papillomavirus Which Causes Cervical Cancer 1645 2Gen Probe Begins U S Clinical Study of Molecular Test for Human Papillomavirus Which Causes Cervical Cancer 1645 3Gen Probe Begins U S Clinical Study of Molecular Test for Human Papillomavirus Which Causes Cervical Cancer 1645 4Gen Probe Begins U S Clinical Study of Molecular Test for Human Papillomavirus Which Causes Cervical Cancer 1645 5Researchers study why high school boys dodge Phys Ed 15567 1Researchers study why high school boys dodge Phys Ed 15567 2
...N FRANCISCO, Calif., July 03, 2007,/PRNewswire-Fir...ounced that Eric Bjerkholt, Sunesis, Senior Vice P...present a company update at,the C. E. Unterberg, T...at 9:00 a.m. Eastern Time in New York, NY. , Inter...tation by,visiting the Sunesis website at <a targe...
..., Mass.--(BUSINESS WIRE)--Jul 2, 2007 - ViaCell, I...er, President and,Chief Executive Officer of ViaCe...ies and product pipeline at the C.E. Unterberg,To...uesday, July,10, 2007 at 3:00 p.m. at the Mandarin...ast of the presentation will be available on,the I...
Other Medicine Technology:Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin,Emerging Growth Conference 2
... F 265 is a highly accurate portable, waterproof s...e measurements. Temperature compensated pH results...e (ATC) or a 3-in-1 electrode. • This GLP/GMP...connect to a printer or a computer. Up to 100 data...
... F 255 is a portable, waterproof system for routin...ements. Temperature compensated pH results can be ...or a 3-in-1 electrode. • Fast and easy one-, ...tomatic buffer recognition for five buffers (pH 1....
... F 295 is a fully equipped, waterproof system for ... temperature measurements. Temperature compensated...rature probe (ATC) or a 3-in-1 electrode. Up to fi...MP compliant system includes an RS-232 interface t...
...lide doors, 8 shelves. Over-sized compressor. T...uorescent interior lighting. Self-Contained Syste...rd. Full One Year Warranty on Parts & Labor and a... available as a chromatography unit which includes...
Medicine Products: